Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded up 2.6% during mid-day trading on Wednesday . The stock traded as high as $165.50 and last traded at $163.81, with a volume of 257,287 shares trading hands. The stock had previously closed at $159.59.

Several equities research analysts recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $239.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday. Cantor Fitzgerald assumed coverage on Intercept Pharmaceuticals in a research note on Wednesday, July 6th. They set a “sell” rating and a $58.00 price objective for the company. Robert W. Baird reissued an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 15th. Needham & Company LLC reissued a “buy” rating and set a $350.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, May 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $187.98.

The stock’s market cap is $4.12 billion. The firm has a 50-day moving average price of $148.27 and a 200-day moving average price of $134.23.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($3.60) by $1.57. During the same quarter in the previous year, the firm posted ($1.78) earnings per share. Analysts expect that Intercept Pharmaceuticals Inc. will post ($16.94) earnings per share for the current fiscal year.

In related news, CEO Mark Pruzanski sold 714 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lisa Bright sold 251 shares of the stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total transaction of $34,512.50. Following the completion of the transaction, the insider now directly owns 18,855 shares of the company’s stock, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have made changes to their positions in ICPT. Rhumbline Advisers increased its position in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares during the last quarter. BB Biotech AG increased its position in shares of Intercept Pharmaceuticals by 21.4% in the fourth quarter. BB Biotech AG now owns 255,719 shares of the biopharmaceutical company’s stock worth $38,192,000 after buying an additional 45,000 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock worth $18,710,000 after buying an additional 6,461 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 578 shares during the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.